Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$45.93
$41.33
$19.76
▼
$48.78
$5.03B0.391.73 million shs1.16 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+1.98%+23.50%+4.29%+101.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$45.93
$41.33
$19.76
▼
$48.78
$5.03B0.391.73 million shs1.16 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+1.98%+23.50%+4.29%+101.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.58
Moderate Buy$52.8315.03% Upside

Current Analyst Ratings Breakdown

Latest EWTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/5/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Reiterated RatingUnderperform$85.00
11/5/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Lower Price TargetOutperform$53.00 ➝ $51.00
10/16/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Initiated CoverageOutperform
10/15/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Reiterated RatingSell (D-)
10/14/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Reiterated RatingBuy
9/21/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Boost Price TargetBuy$45.00 ➝ $57.00
8/20/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Boost Price TargetOverweight$53.00 ➝ $60.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M$8.195.61N/AN/AN/A-7.15%-6.65%N/A

Latest EWTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.5316$9.65+$10.1816$9.65$119.23 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
12.30
12.30

Institutional Ownership

CompanyInstitutional Ownership
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
133109.48 million86.16 millionOptionable

Recent News About These Companies

Research Analysts Offer Predictions for EWTX FY2028 Earnings
Equities Analysts Issue Forecasts for EWTX FY2026 Earnings
Edgewise Therapeutics (NASDAQ:EWTX) Stock Jumps 14% - Time to Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$45.93 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$45.97 +0.04 (+0.09%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.